Overview
Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist marketed by Eli Lilly under the brand name Trulicity. Approved by the FDA in September 2014 for type 2 diabetes, dulaglutide consists of two GLP-1 analog molecules covalently linked to a modified human IgG4 Fc fragment, which extends its half-life and supports once-weekly subcutaneous dosing. The REWIND cardiovascular outcomes trial in 9,901 patients with type 2 diabetes demonstrated a 12% relative risk reduction in major adverse cardiovascular events over a median 5.4 years, making dulaglutide one of only a few GLP-1 agents with confirmed primary-prevention cardiovascular benefit. Dulaglutide is widely used as a comparator in head-to-head trials of newer agents such as tirzepatide.
Mechanism of Action
Dulaglutide activates the GLP-1 receptor, stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing inappropriate glucagon release from alpha cells, slowing gastric emptying, and acting on hypothalamic centers to reduce appetite. The Fc fusion protects the peptide from DPP-4 degradation and confers a half-life of approximately 4.5 to 4.7 days, supporting steady-state plasma exposure within 2 to 4 weeks of weekly dosing. Cardiovascular benefit is thought to involve direct vascular GLP-1 receptor effects, anti-inflammatory action on macrophages, modest blood pressure reduction, and weight-mediated improvements in glycemia.
Potential Benefits
- FDA-approved for type 2 diabetes (Trulicity, 2014) and reduction of major adverse cardiovascular events in adults with T2D and established CV disease or multiple CV risk factors
- REWIND trial: 12% relative risk reduction in MACE over 5.4 years (HR 0.88, 95% CI 0.79-0.99)
- HbA1c reduction of approximately 1.0 to 1.5 percent across pivotal AWARD trials
- Modest weight loss (typically 2 to 3 kg)
- Once-weekly subcutaneous dosing via prefilled pen
- Established safety and efficacy profile from over a decade of post-marketing use
Research Dosage Notes
The following reflects doses used in published research studies. This is not medical advice.
Starting dose 0.75 mg subcutaneously once weekly. May increase to 1.5 mg weekly for additional glycemic control. Doses of 3 mg and 4.5 mg weekly are also available for further A1C reduction. Half-life approximately 4.7 days.
Amino Acid Sequence
Two GLP-1 analog peptides (A8G, G22E, R36G modifications) linked via small peptide spacer to human IgG4 Fc fragment
Side Effects & Safety
- Nausea, diarrhea, vomiting (dose-related, typically transient)
- Decreased appetite
- Injection site reactions
- Increased risk of acute pancreatitis (rare)
- Boxed warning for thyroid C-cell tumors based on rodent studies
- Gallbladder disease risk
Synergistic Compounds
The following compounds have been studied alongside Dulaglutide for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Sets July 23-24 PCAC Vote on Seven Peptides for the 503A Bulks List: BPC-157, KPV, TB-500, MOTs-C, DSIP, Semax, Epitalon
FDA's July 23-24 PCAC will vote on seven peptides for the 503A Bulks List. Two dockets are open. July 9 is the cutoff for comments to reach the committee.
Tirzepatide Linked to Fewer Cardiac Events After PCI and TAVR: Three Propensity-Matched Studies at SCAI 2026 and AACE 2026
Three propensity-matched studies presented April 23-24 link tirzepatide to fewer deaths and major cardiovascular events versus GLP-1 comparators in PCI, TAVR, and obese hypothyroid populations.
Tirzepatide vs Semaglutide Cost-Effectiveness: SURMOUNT-5 Lifetime Model Shows $41,688 Per-Patient Savings
A new lifetime simulation built on SURMOUNT-5 data finds tirzepatide saves $41,688 per patient and adds 0.506 QALYs versus semaglutide.
FDA Opens Docket FDA-2025-N-6895 for July 2026 PCAC Peptide Review
FDA opened docket FDA-2025-N-6895 ahead of the July 23–24, 2026 PCAC meeting on seven peptides. What is on the agenda and what stays unchanged for 503A compounding.